MHRA and NICE announced a streamlined approval process intended to help patients in England receive some new medicines three to six months earlier. The agencies say the aligned pathway and an improved advice service are designed to support faster access and help companies plan with more certainty.
For PV readers, this matters because faster access pathways can increase the importance of strong post-authorisation readiness. When timelines compress upstream, organizations may need to be even more disciplined downstream in safety monitoring, risk communication, and lifecycle oversight. That is an inference based on the nature of the pathway change.
0 Comments